

ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES

VACCINES FOR CHILDREN PROGRAM

VACCINES TO PREVENT HUMAN PAPILLOMAVIRUS

The purpose of this resolution is to reflect the new dosing schedules for human papillomavirus vaccine.

VFC Resolution 02/15-2 is repealed and replaced by the following:

Eligible Groups

All children aged 9 through 18 years.

Recommended schedule and intervals

ACIP recommends routine HPV vaccination at age 11 or 12 years, and vaccination can be given starting at age 9 years. ACIP also recommends vaccination for females and males age 13 through 18 years who were not adequately vaccinated previously.

The table below summarizes the recommended number of recommended HPV vaccine doses and schedule for specific groups of children.

Recommended number of doses	Recommended dosing schedule	Population
2	0, 6–12 months ¹	Persons initiating vaccination at age 9 through 14 years, except immunocompromised persons ²
3	0, 1–2, 6 months ³	Persons initiating vaccination at age 15 through 18 years, and immunocompromised persons ² initiating vaccination at 9 through 18 years

Table Notes:

1. In a 2-dose schedule of HPV vaccine, the minimum interval is 5 months between the first and the second dose.
2. Persons with primary or secondary immunocompromising conditions that might reduce cell-mediated or humoral immunity.
3. In a 3-dose schedule of HPV vaccine, the minimum intervals are 1 month between the first and second dose, 3 months between the second and third dose, and 5 months between the first and third dose.

Persons who initiated vaccination with 9vHPV, 4vHPV, or 2vHPV before the 15th birthday, and received 2 doses at the recommended dosing schedule, or 3 doses at the recommended dosing schedule, are considered adequately vaccinated.

Persons who initiated vaccination with 9vHPV, 4vHPV, or 2vHPV on or after the 15th birthday, and received 3 doses at the recommended dosing schedule, are considered adequately vaccinated.

Vaccine doses administered at shorter than minimum intervals should be re-administered as recommended.

9vHPV may be used to continue or complete a series started with another HPV vaccine.

If the vaccine schedule is interrupted, the series does not need to be restarted.

Recommended dosage

Refer to product package inserts.

Precautions and contraindications

Precautions and contraindications can be found in the package inserts available at: <http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833>.

[If an ACIP recommendation regarding the human papillomavirus vaccination is published within 12 months following this resolution, the relevant language above (except in the eligible groups sections) will be replaced with the language in the recommendation and incorporated by reference to the publication URL.]

Adopted and Effective: October 19, 2016

This document can be found on the CDC website at: <https://www.cdc.gov/vaccines/programs/vfc/providers/resolutions.html>